Results 191 to 200 of about 104,183 (265)

Molecular Signature of Cisplatin Resistance in Ovarian Cancer Identifies Therapeutic Opportunities for Re-sensitization. [PDF]

J Cancer
Mansour M, van Ginkel S, Alata M, Bani I, Elhussin I.   +4 more
europepmc   +1 more source

The FGF/FGFR System in the Biology and Therapeutic Landscape of Pediatric CNS Tumors

Medicinal Research Reviews, EarlyView.
ABSTRACT Central nervous system (CNS) tumors are the most common solid malignancies in children, comprising a highly heterogeneous group of neoplasms defined by distinct molecular alterations and clinical behaviors. Advances in molecular genetics have underscored the relevance of specific signaling pathways in driving pediatric tumorigenesis, among ...
Serena Filiberti, Camilla Tavani, Elena Somenza, Nicolas Tassone, Antonio d'Amati, Marta Turati, Roberto Ronca   +6 more
wiley   +1 more source

Dual-activated fluorescent probe for the study of the mechanism of SO₂ and NO in cisplatin resistance of nasopharyngeal carcinoma. [PDF]

RSC Adv
Wang X, Li X, Chen X, Wang D.
europepmc   +1 more source

Myasthenia Gravis and Thymoma

Muscle &Nerve, EarlyView.
ABSTRACT Thymoma is the most common tumor of the anterior mediastinum. Approximately 20%–30% of patients with a thymoma develop myasthenia gravis (MG), and an additional one third may possess positive acetylcholine receptor (AChR) antibodies without MG.
Benjamin Claytor, Lukas Delasos, Daniel P. Raymond, Erik Seroogy, Jason Lempel, Yuebing Li   +5 more
wiley   +1 more source

Regulation of cisplatin resistance in lung cancer by epigenetic mechanisms. [PDF]

Clin Epigenetics
Yu X, Jia L, Tang Q, Zhou Q, Wang G, Wang S.   +5 more
europepmc   +1 more source

Traditional Chinese Medicine for lung cancer: Mechanisms, clinical evidence, and future perspectives

Precision Medical Sciences, EarlyView.
Graphical abstract represents the risk factors for lung cancer, TCM efficacy and clinical outcomes to future challenges. Abstract Lung cancer remains a leading cause of global cancer mortality. Despite advances in conventional treatments such as surgery, chemotherapy, targeted therapy, and immunotherapy, challenges including drug resistance, toxicity ...
Zhangdeng Chen, Liujun Bao
wiley   +1 more source

ABCC6 Transporter Contributed to Cisplatin Resistance on Bladder Cancer. [PDF]

Int J Med Sci
Chou KY, Chang AC, Hwang TI, Tsai TF, Ho CY, Liu HW, Achudhan D, Tang CH, Lin YY.   +8 more
europepmc   +1 more source

COX5A promotes cell progression and cisplatin‐resistance by alleviating mitochondrial dysfunction in head and neck squamous cell carcinoma

Precision Medical Sciences, EarlyView.
COX5A promotes cell progression and cisplatin‐resistance and alleviates mitochondrial dysfunction. ISG15 shows a reversing role with COX5A. Targeting the COX5A‐mediated mitochondrial metabolic pathway may offer a novel therapeutic approach to enhance cisplatin sensitivity in HNSCC.
Nannan Guo, Zhangyu Yao, Bo Gui, Qingya Sun, Yihan Tang, Tingting Hu, Yanbin Zhao, Fangzhou Liu   +7 more
wiley   +1 more source

RETRACTION: Elevated Glutathione Peroxidase 2 Expression Promotes Cisplatin Resistance in Lung Adenocarcinoma. [PDF]

Oxid Med Cell Longev
Cellular Longevity OMA.
europepmc   +1 more source

Mechanistic Learning for Predicting Survival Outcomes in Head and Neck Squamous Cell Carcinoma

CPT: Pharmacometrics &Systems Pharmacology, Volume 14, Issue 3, Page 540-550, March 2025.
ABSTRACT We employed a mechanistic learning approach, integrating on‐treatment tumor kinetics (TK) modeling with various machine learning (ML) models to address the challenge of predicting post‐progression survival (PPS)—the duration from the time of documented disease progression to death—and overall survival (OS) in Head and Neck Squamous Cell ...
Kevin Atsou, Anne Auperin, Jôel Guigay, Sébastien Salas, Sebastien Benzekry   +4 more
wiley   +1 more source